Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Maria Ripps maintains a Buy rating on Hims & Hers Health (NYSE:HIMS) and raises the price target from $20 to $24.
May 22, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Maria Ripps maintains a Buy rating on Hims & Hers Health and raises the price target from $20 to $24.
The raised price target and maintained Buy rating from a reputable analyst are likely to positively influence investor sentiment and drive short-term price appreciation for HIMS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100